Dr Shruti Desai, Radboud University Nijmegen Medical Center features in latest Neuronet campaign

2020-11-26T18:50:35+00:00September 28th, 2020|News, Partner in the Spotlight|

Dr Shruti Desai is a postdoctoral researcher and Cellular Bioenergetics group member at Radboud University Nijmegen Medical Center within the Radboud Center for Mitochondrial Medicine (RCMM). Here, she works alongside mitochondrial experts on clinical care, diagnostics and fundamental research to conduct morphofunctional in vitro studies in living and fixed cells using super-resolution analysis of mitochondria. On September 24, 2020, Shruti responded to questions about her work for the Neuronet project (https://www.imi-neuronet.org/) as part of their series of interviews where they [...]

Neuronet launches campaign: “The value of public-private collaboration & findings highlights”

2020-10-19T11:33:29+01:00September 11th, 2020|News|

The Neuronet project (https://www.imi-neuronet.org/) is currently comprised of 18 IMI projects, including PD-MitoQUANT. Today, September 11, 2020, they have launched a new platform to boost collaboration across research projects focusing on neurodegenerative diseases. Neuronet’s communication team and our community of communication representatives from the Innovative Medicines Initiative projects on neurodegeneration are pleased to celebrate the great people behind the projects through an annual Neuronet campaign on social media. A profile of Dr Orla Watters, a member of the PD-MitoQUANT research team [...]

PROJECT FACTS

 

  • Grant agreement number 821522
  • IMI2 JU contribution €4,617,933.75
  • Duration 36 months
  • Starting date 1 February 2019

 

FUNDING ACKNOWLEDGEMENT

 

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821522. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

The material presented and views expressed here reflect the author’s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

 

Go to Top